Health Ministry proposes curbs on prescription drug ads by pharmacies
Synopsis
India's Health Ministry wants to make it illegal for pharmacies and wholesalers to advertise prescription medicines — not just manufacturers. The draft amendment covers 500-plus Schedule H drugs, follows a DTAB recommendation, and arrives alongside a separate CCTV mandate for medical stores, signalling a systematic tightening of India's prescription drug supply chain.
Key Takeaways
The Union Ministry of Health and Family Welfare on 9 October 2026 proposed extending prescription drug advertisement restrictions to pharmacies, wholesalers , and licensed drug sellers.
Medicines under Schedules H, H1 , and X of the Drugs Rules, 1945 would require Central Government prior approval before being advertised.
Schedule H alone covers more than 500 medicines , making the scope of the proposal wide-reaching.
The draft follows recommendations from the 93rd DTAB meeting held in February 2026 .
Public objections and suggestions can be submitted within 30 days of Gazette notification.
The proposal comes a month after the ministry separately proposed mandatory CCTV at all medical stores with three-month recording retention.
The Union Ministry of Health and Family Welfare on 9 October 2026 released a draft amendment proposing stricter controls on the advertisement of prescription medicines, extending existing restrictions beyond pharmaceutical manufacturers to cover pharmacies, wholesalers, and other licensed drug sellers across India. The proposal marks a significant widening of regulatory oversight over prescription drug promotion in the country.
What the Draft Rules Propose
Under the draft amendment, medicines listed under Schedules H, H1, and X of the Drugs Rules, 1945 — which include several antibiotics, psychotropic substances, and other prescription-only drugs — would require prior approval from the Central Government before being advertised. The ministry has proposed inserting a new sub-rule (22) under Rule 65 of the Drugs Rules to formalise this wider scope.
Currently, advertisement restrictions apply primarily to pharmaceutical companies that manufacture these medicines. The proposed change would bring retail medical stores and wholesale drug dealers — entities licensed to sell, stock, exhibit, offer for sale, or distribute drugs — under the ambit of advertisement controls for the first time.
Why This Matters
Officials believe the proposed changes will reduce the risk of self-medication and ensure that medicines requiring professional medical supervision are not marketed directly to consumers without adequate safeguards. Schedule H alone covers more than 500 medicines commonly used in medical treatment, making the scope of the proposal significant.
Notably, the move is part of a broader effort to tighten controls over the sale of prescription drugs. Last month, the Health Ministry separately proposed making CCTV surveillance mandatory at all medical stores, with recordings required to be preserved for at least three months — a measure also aimed at curbing unauthorised access to Schedule H, H1, and X medicines.
Background: DTAB Recommendations
The draft amendment follows recommendations made during the 93rd meeting of the Drugs Technical Advisory Board (DTAB), held in February 2026. The board had identified a regulatory gap — existing law addressed advertisement by manufacturers but lacked explicit provisions covering licensees engaged in the sale and distribution of drugs. The current proposal is the ministry's legislative response to that gap.
What Happens Next
Stakeholders and members of the public have been invited to submit objections and suggestions within 30 days from the date copies of the Gazette notification containing the draft rules are made available. If notified in final form, the amendments are expected to strengthen regulatory safeguards around prescription drugs and enhance accountability across India's drug distribution network.
Point of View
The retail end of the supply chain largely did not. In a country where self-medication is widespread and antibiotic resistance is a growing public health concern, that gap has had real consequences. The CCTV mandate for pharmacies proposed last month and this advertisement curb together suggest a more systematic regulatory approach — but enforcement, as always in India's fragmented drug retail sector, will be the decisive variable. Thirty days of public comment is also a narrow window for an amendment that affects hundreds of thousands of licensed drug sellers across the country.
NationPress
9 Oct 2026
Frequently Asked Questions
What has the Health Ministry proposed regarding prescription drug advertisements?
The Union Ministry of Health and Family Welfare has proposed extending advertisement restrictions on prescription medicines to include pharmacies, wholesalers, and all licensed drug sellers — not just manufacturers. Under the draft rules, medicines under Schedules H, H1, and X would require prior Central Government approval before being advertised.
Which medicines are covered under the proposed rules?
The draft rules cover medicines listed under Schedules H, H1, and X of the Drugs Rules, 1945, which include antibiotics, psychotropic substances, and other prescription-only drugs. Schedule H alone covers more than 500 medicines commonly used in medical treatment.
Why is the Health Ministry proposing these changes?
Officials say the changes are intended to reduce the risk of self-medication and prevent prescription medicines from being marketed directly to consumers without adequate safeguards. The proposal also follows a recommendation from the 93rd meeting of the Drugs Technical Advisory Board (DTAB) in February 2026, which identified a regulatory gap for drug sellers and distributors.
How can the public respond to the draft amendment?
Stakeholders and members of the public can submit objections and suggestions within 30 days from the date copies of the Gazette notification containing the draft rules are made available. The ministry has invited feedback before the rules are finalised.
Is this proposal connected to other recent pharmacy regulations?
Yes. The Health Ministry last month separately proposed making CCTV surveillance mandatory at all medical stores, with recordings to be preserved for at least three months, also aimed at curbing unauthorised sale of Schedule H, H1, and X medicines. Together, the two proposals form part of a broader effort to tighten oversight across India's prescription drug supply chain.
